The groundbreaking, uniquely robust Robert A. Winn Diversity in Clinical Trials Award Program is on track to train more than 500 individuals from diverse backgrounds by 2027
Collaboration to target bacterial and viral pathogens including HIV, SARS-CoV-2, antimicrobial-resistant pathogens, and tuberculosis
If authorized by the USFDA, the Proof Lab Test System may be used to deliver accurate, actionable, lab-quality results for Covid-19 in as little as 18 minutes
The findings support the fact that further extension of nationwide cardiovascular disease (CVD) risk identification programs and prevention strategies to reduce the occurrence of cardiovascular diseases are warranted
The new facility is scheduled to start operation in the first half of 2024
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
Supply increase to help meet growing global demand
The new structure further transitions the Health Care business line into a system solutions partner for the pharmaceutical and biotech industries
BVX-0922 to target colorectal cancer under investigator-sponsored IND
A novel second-generation approach to achieve a safe, durable, and stable transgene expression to overcome the challenges of factor VIII replacement therapies
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
